Weight loss drugs are making headlines these days—maybe you’ve heard the buzz about medications like Ozempic or Wegovy. While they’ve become a hot topic, they also bring some weighty decisions when it comes to your benefits plan.

Here’s the skinny:

  • These drugs are expensive. Covering them can drive up your company’s benefits costs, and for employees paying out of pocket, the sticker shock is real.

  • No generics until 2033. Patent protections mean a lower-cost alternative is still years away, keeping prices high for the foreseeable future.

  • To cover or not to cover? That’s the question.

    • Not covering them could save your company money right now.
    • Covering them could lead to long-term savings by reducing the costs of chronic conditions like diabetes that often go hand-in-hand with weight issues.
  • The perk perspective. If you offer these drugs, it could set your benefits apart and attract top talent. On the flip side, if you don’t cover them, some employees might look for a company that does.

  • Brokers know best. Your benefits broker can help you determine what's right for your organization's unique needs.

Ultimately, this is a decision that impacts your business, your team, and your budget. It’s worth considering all angles before stitching it into your plan.

If you’re unsure what’s right for your organization, we’re here to help. Let’s talk about what’s best for your business and how to keep your benefits strategy strong.

Let's strategize together

Recommended For You

What are Fringe Benefits and How Do They Work?

What are Fringe Benefits and How Do They Work?

Barbara Collins
Barbara Collins October 13, 2025
Getting Hybrid Work Right: How to Get the Most out of your Hybrid and Remote Work Model Employee Engagement Engagement Workforce Management

Getting Hybrid Work Right: How to Get the Most out of your Hybrid and Remote Work Model

Gather Sciences October 12, 2025
Independent Contractor vs. Employee: A Guide

Independent Contractor vs. Employee: A Guide

Barbara Collins
Barbara Collins October 7, 2025